Skip to main content
Premium Trial:

Request an Annual Quote

GeneSoft Gets Another $5.5M from Department of Defense for DNA-Targeting Antibiotics

NEW YORK, April 18 - GeneSoft Pharmaceuticals said today that it has received another $5.5 million in funding from the US Department of Defense to develop small molecule drugs that target specific DNA sequences in biowarfare agents.

 

The funding is in addition to $15.3 million the South San Francisco-based company has already received over the last four years for an ongoing contract with the Defense Advanced Research Project Agency and the US Army.

 

GeneSoft, which licenses its DNA-binding technology from the University of Geneva in Switzerland, develops novel anti-infective agents that interfere with gene expression and DNA replication by binding to specific DNA sequences.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.